Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter van der Ley

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Journal of Endotoxin Research|June 14, 2003
Lessons from an LPS-deficient Neisseria meningitidis mutantPeter van der Ley, Liana Steeghs
Expert Review of Vaccines|March 24, 2015
Biosynthetically engineered lipopolysaccharide as vaccine adjuvantAfshin Zariri, Peter van der Ley
Current Opinion in Immunology|August 20, 2023
Outer membrane vesicle-based intranasal vaccinesPeter Van der Ley, Virgil Ejc Schijns
Human Vaccines|July 26, 2011
Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutantsPeter van der Ley, Germie van den Dobbelsteen
Analytical Chemistry|November 22, 2021
Nanoflow LC-MS Method Allowing In-Depth Characterization of Natural Heterogeneity of Complex Bacterial LipopolysaccharidesElder Pupo, Peter van der Ley, Hugo D Meiring
Microlife|May 24, 2023
Lipid A heterogeneity and its role in the host interactions with pathogenic and commensal bacteriaSukumar Saha, Elder Pupo, Afshin Zariri, et al.
Biotechnology Journal|February 26, 2016
Outer membrane vesicles as platform vaccine technologyLeo van der Pol, Michiel Stork, Peter van der Ley
Vaccine|May 1, 2007
TLR4-dependent adjuvant activity of Neisseria meningitidis lipid ASusu Zughaier, Liana Steeghs, Peter van der Ley, et al.
The Journal of Biological Chemistry|February 5, 2014
Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist propertiesElder Pupo, Hendrik-Jan Hamstra, Hugo Meiring, et al.
Infection and Immunity|October 3, 2007
Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup BFloris Fransen, Claire J Boog, Jos P van Putten, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Journal of Endotoxin Research|June 14, 2003
Lessons from an LPS-deficient Neisseria meningitidis mutantPeter van der Ley, Liana Steeghs
Expert Review of Vaccines|March 24, 2015
Biosynthetically engineered lipopolysaccharide as vaccine adjuvantAfshin Zariri, Peter van der Ley
Current Opinion in Immunology|August 20, 2023
Outer membrane vesicle-based intranasal vaccinesPeter Van der Ley, Virgil Ejc Schijns
Human Vaccines|July 26, 2011
Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutantsPeter van der Ley, Germie van den Dobbelsteen
Analytical Chemistry|November 22, 2021
Nanoflow LC-MS Method Allowing In-Depth Characterization of Natural Heterogeneity of Complex Bacterial LipopolysaccharidesElder Pupo, Peter van der Ley, Hugo D Meiring
Microlife|May 24, 2023
Lipid A heterogeneity and its role in the host interactions with pathogenic and commensal bacteriaSukumar Saha, Elder Pupo, Afshin Zariri, et al.
Biotechnology Journal|February 26, 2016
Outer membrane vesicles as platform vaccine technologyLeo van der Pol, Michiel Stork, Peter van der Ley
Vaccine|May 1, 2007
TLR4-dependent adjuvant activity of Neisseria meningitidis lipid ASusu Zughaier, Liana Steeghs, Peter van der Ley, et al.
The Journal of Biological Chemistry|February 5, 2014
Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist propertiesElder Pupo, Hendrik-Jan Hamstra, Hugo Meiring, et al.
Infection and Immunity|October 3, 2007
Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup BFloris Fransen, Claire J Boog, Jos P van Putten, et al.
Pageof 8